FIBK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FIBK is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near resistance, analyst sentiment is mixed-to-negative, insiders are heavy sellers, and options positioning is bearish. While the latest quarter showed better net income and the technical trend is constructive, the overall setup does not support an aggressive immediate buy at this price.
The chart trend is bullish but extended in the near term. MACD histogram is positive and expanding, and moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports an upward trend. RSI_6 at 66.59 is near overbought but still not a strong sell signal. Price at 36.24 is close to R1 resistance at 36.467 and below R2 at 37.057, so upside from here looks limited unless it breaks above resistance decisively. The pre-market price is above the pivot at 35.512, which is supportive, but the current level is not an ideal low-risk entry for a patient long-term buyer.
The technical trend remains constructive with bullish moving-average alignment and expanding positive MACD. Q1 net income rose 19.92% year over year, showing improved profitability. There is no adverse news in the last week. UBS and Stephens both raised price targets on May 1, and Piper Sandler remains Overweight, which shows some analyst support despite mixed ratings overall.
Analyst sentiment is mixed and leaning cautious, with UBS maintaining a Sell rating and Keefe Bruyette downgrading the stock to Market Perform. Insiders have been selling heavily, with selling up 1788.50% over the last month. Options positioning is bearish with a 2.82 put-call open interest ratio. Revenue was flat year over year, and EPS was reported at 0, which limits the strength of the financial growth story. No recent bullish news catalyst is present.
In Q1 2026, revenue was 236.7 million, flat year over year, while net income increased 19.92% to 60.2 million. That indicates improved bottom-line efficiency, but top-line growth remains weak. EPS dropped to 0 year over year, which is not a strong fundamental signal for a long-term accumulation case. The latest quarter season was Q1 2026.
Wall Street views are divided. UBS raised its price target to $33 from $30 but kept a Sell rating, showing continued skepticism. Stephens lifted its target to $36 from $34 and kept an Equal Weight rating. Keefe Bruyette downgraded the stock to Market Perform from Outperform and trimmed its target to $37, citing more balanced risk/reward and the need for loan stabilization. Piper Sandler is still constructive with an Overweight rating and a $41 target, but the recent trend in ratings is clearly more cautious overall.
